3,3′,5-triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy

Journal of Endocrinology

Volumn 193, Issue 2, 2007, Pages 209-223

  Michienzi, Simona ^a,b   Bucci, Barbara ^b   Falzacappa, Cecilia Verga ^a,b   Patriarca, Valentina ^a,b   Stigliano, Antonio ^a,b   Panacchia, Laura ^c   Brunetti, Ercole ^b   Toscano, Vincenzo ^a,b   Misiti, Silvia ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; FLUOROURACIL; GEMCITABINE; PLACEBO; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CCND2 PROTEIN, HUMAN; CYCLINE; DEOXYCYTIDINE; DRUG DERIVATIVE; LIOTHYRONINE; P21 ACTIVATED KINASE; PROTEIN SERINE THREONINE KINASE; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DIPLOIDY; DRUG POTENTIATION; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; CELL CYCLE; COMPARATIVE STUDY; DRUG EFFECT; FLOW CYTOMETRY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DEOXYCYTIDINE; DRUG SYNERGISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, THYROID HORMONE; TRIIODOTHYRONINE;

EID: 34250334692     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/joe.1.07065     Document Type: Article

References (75)

1. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS & Meyskens FL Jr 1998 Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Ontology Group Study. Cancer Research 58 1149-1158.
2. Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, Gouma DJ & Obertop H 1995 Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 75 2069-2076.
3. Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, Lillemoe KD, Pitt HA, Lin P & Cameron JL 1998 DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. Journal of Surgical Oncology 67 151-159.
4. Ballock RT, Zhou X, Mink LM, Chen DH, Mita BC & Stewart MC 2000 Expression of cyclin-dependent kinase inhibitors in epiphyseal chondrocytes induced to terminally differentiate with thyroid hormone. Endocrinology 141 4552-4557.
5. Biliran H Jr, Wang Y, Banejee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH & Liao JD 2005 Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic turner cell line. Clinical Cancer Research 11 6075-6086.
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Wilhams J, Lengauer C, Kinzler KW & Vogelstein B 1999 Disruption of p53 in human cancer cells alters the responses to therapeutic agents. Journal of Clinical Investigation 104 263-269.
7. Chang BD, Swift ME, Shen M, Fang J, Broude EV & Roninson IB 2002 Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. PNAS 99 389-394.
8. Conlon KC, Klimstra DS & Brennan MF 1996 Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Annals of Surgery 223 273-279.
9. Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM & Palumbo G 2006 Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Molecular Cancer Therapeutics 5 776-795.
10. Cronauer MV, Klocker H, Talasz H, Geisen FH, Hobisch A, Radmayr C, Bock G, Culig Z, Schirmer M, Reissigl A et al. 1996 Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 28 172-181.
11. Cusinato F, Pighin L Luciani S & Trevisi L 2006 Synergism between staurosporine and drugs inducing endoplasmic reticulum stress. Biochemical Pharmacology 28 1562-1569.
12. D'Arezzo S, Incerpi S, Davis FB, Acconcia F, Marino M, Farias RN & Davis PJ 2004 Rapid nongenomic effects of 3,5,3′-triiodo-L-thyronine on the intracellular pH of L-6 myoblasts are mediated by intracellular calcium mobilization and kinase pathways. Endocrinology 145 5694-5703.
13. Davis PJ & Davis FB 1996 Nongenomic actions of thyroid hormone. Thyroid 6 497-504.
14. Deshpande A, Sicinski P & Hinds PW 2005 Cyclins and cdks in development and cancer: a perspective. Oncogene 24 2909-2915.
15. Dinda S, Sanchez A & Moudgil V 2002 Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21 761-768.
16. Edge SB, Schmieg RE Jr, Rosenlof LK & Wilhelm MC 1993 Pancreas cancer resection outcome in American University centers in 1989-1990. Cancer 71 3502-3508.
17. Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E & Schmidt J 2004 The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World Journal of Gastroenterology 10 3583-3589.
18. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240 889-895.
19. Finlayson EV & Birkmeyer JD 2003 Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. Journal of the American College of Surgeons 196 410-417.
20. Garcia-Silva S, Perez-Juste G & Aranda A 2002 Cell cycle control by the thyroid hormone in neuroblastoma cells. Toxicology 27 179-182.
21. Ghaneh P, Kawesha A, Evans JD & Neoptolemos JP 2002 Molecular prognostic markers in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery 9 1-11.
22. Giovannetti E, Mey V, Danesi R, Mosca I & Del Tacca M 2004 Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clinical Cancer Research 10 2936-2943.
23. Glass CK 1994 Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocrine Reviews 15 391-407.
24. Halloran CM, Ghaneh P, Bosonnet L, Hartley MN, Sutton R & Neoptolemos JP 2002 Complications of pancreatic cancer resection. Digestive Surgery 19 138-146.
25. Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP & Costello E 2004 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p161NK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. Journal of Gene Medicine 6 514-525.
26. Herwig S & Strauss M 1997 The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. European Journal of Biochemistry 246 581-601.
27. Huang P, Chubb S, Hertel LW, Grindey GB & Plunkett W 1991 Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Research 51 6110-6117.
28. Kopper L, Zalatnai A & Timar J 2005 Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy? Pathology Oncology Research 11 69-73.
29. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV & Korc M 1999 Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistatice genes. Cancer Research 59 3505-3511.
30. Kulke MH 2003 Advanced pancreatic cancer: is there a role for combination therapy? Expert Review of Anticancer Therapy 3 729-739.
31. Kusumoto M, Ogawa T, Mizumoto K, Ueno H, Niiyama H, Sato N, Nakamura M & Tanaka M 1999 Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clinical Cancer Research 5 2140-2147.
32. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Caremni N, Viano I, Colangelo D, Leone R, Apostoli P et al. 1998 Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochemical Pharmacology 55 1247-1254.
33. Lazar MA 1993 Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrine Reviews 14 184-193.
34. Lebel JM, Dussault JH & Puymirat J 1994 Overexpression of the beta 1 thyroid receptor induces differentiation in neuro-2a cells. PNAS 91 2644-2648.
35. Ledda-Columbano GM, Perra A, Loi R, Shinozuka H & Columbano, A 2000 Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Research 60 603-609.
36. Ledda-Columbano GM, Perra A, Pibiri M, Molotzu F & Columbano A 2005 Induction of pancreatic acinar cell proliferation by thyroid hormone. Journal of Endocrinology 185 393-399.
37. Lee WS, Liu CW, Juan SH, Liang YC, Ho PY & Lee YH 2003 Molecular mechanism of progesterone-induced and proliferation in rat aortic smooth muscle cells. Endocrinology 144 2785-2790.
38. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP et al. 1998 p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clinical Cancer Research 4 1243-1250.
39. Longley DB, Harkin DP & Johnston PG 2003 5-Fluorouracil: mechanisms of action and clinical strategies. Nature Reviews. Cancer 3 330-338.
40. Loewe S 1953 The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 285-290.
41. Loewe SW, Ruley HE, Jacks T & Housman DE 1993 p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 957-967.
42. Macdonald JS 2004 Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemotherapy and Pharmacology 54 4-11.
43. Mack PC, Gandara DR, Lau AH, Lara PN Jr, Edelman MJ & Gumerlock PH 2003 Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemotherapy and Pharmacology 51 337-348.
44. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
45. Marchal JA, Boulaiz H, Suarez I, Sainger E, Campos J, Carrillo E, Prados J, Gallo MA, Espinosa A & Aranega A 2004 Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Investigational New Drugs 22 379-389.
46. McKeown NJ, Tews MC, Gossain VV & Shah SM 2005 Hyperthyroidism. Emergency Medicine Clinics of North America 23 669-685.
47. Mirjolet JF, Didelot C, Barberi-Heyob M & Merlin JL 2002 G(1)/S but not G(0)/G(1) cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 48 6-13.
48. Misiti S, Anastasi E, Sciacchitano S, Verga Falzacappa C, Panacchia L, Bucci B, Khouri D, D'Acquarica I, Brunetti E, Di Mario U et al. 2005 3,5,3′-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a beta-cell-Like phenotype. Journal of Cellular Physiology 204 286-296.
49. Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM & Gold DV 2004 Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Research 64 8405-8410.
50. van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VW, Kroep JR, Pinedo HM & Peters GJ 2000 Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochimica et Biophysica Acta 1474 5-12.
51. Mosca F, Giulianotti PC, Balestracci T, Di Candio G, Pietrabissa A, Sbrana F & Rossi G 1997 Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 122 553-566.
52. Mose S, Class R, Weber HW, Rahn A, Brady LW & Bottcher HD 2003 Radiation enhancement by gemcitabine-mediated cell cycle modulations. American Journal of Clinical Oncology 26 60-69.
53. Ng SSW, Tsao MS, Chow S & Hedley DW 2000 Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Research 60 5451-5455.
54. Nitecki SS, Sarr MG, Colby TV & van Heerden JA 1995 Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Annals of Surgery 221 59-66.
55. Nygard M, Wahlstrom GM, Gustafsson MV, Tokumoto YM & Bondesson M 2003 Hormone-dependent repression of the E2F-1 gene by thyroid hormone receptors. Molecular Endocrinology 17 79-92.
56. Otto AM, Paddenberg R, Schubert S & Mannherz HG 1996 Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. Journal of Cancer Research and Clinical Oncology 122 603-612.
57. Park MT & Lee SJ 2003 Cell cycle and cancer. Journal of Biochemistry and Molecular Biology 36 60-65.
58. Pauwels B, Korst AE, Lardon F & Vermorken JB 2005 Combined modality therapy of gemcitabine and radiation. Oncologist 10 34-51.
59. Perez-Juste G & Aranda A 1999 The cyclin-dependent kinase inhibitor p27(Kip1) is involved in thyroid hormone-mediated neuronal differentiation. Journal of Biological Chemistry 274 5026-5031.
60. Ribeiro RC, Kushner PJ & Baxter JD 1995 The nuclear hormone receptor gene superfamily. Annual Review of Medicine 46 443-453.
61. Rosenberg L 2000 Pancreatic cancer: a review of emerging therapies. Drugs 59 1071-1089.
62. Ruiz van Haperen VW, Veerman G, Vermorken JB & Peters GJ 1993 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochemical Pharmacology 46 762-766.
63. Saji S, Hirose M & Toi M 2005 Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemotherapy and Pharmacology 56 21-26.
64. Shapiro GI & Harper JW 1999 Anticancer drug targets: cell cycle and checkpoint control. Journal of Clinical Investigation 104 1645-1653.
65. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW & Greenberg AH 1994 Premature p34cdc2 activation required for apoptosis. Science 263 1143-1145.
66. Siddik ZH 2003 Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 7265-7279.
67. Symon Z, Davis M, McGinn CJ, Zalupski MM & Lawrence TS 2002 Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. International Journal of Radiation Ontology, Biology, Physics 53 140-145.
68. Tokumoto YM, Durand B & Raff MC 1999 An analysis of the early events when oligodendrocyte precursor cells are triggered to differentiate by thyroid hormone, retinoic acid, or PDGF withdrawal. Developmental Biology 213 327-339.
69. Umesono K, Murakami KK, Thompson CC & Evans RM 1991 Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65 1255-1266.
70. 3) is a survival factor for pancreatic beta-cells undergoing apoptosis. Journal of Cellular Physiology 206 309-321.
71. 3 in pancreatic β cells. Journal of Molecular Endocrinology 38 221-233.
72. Vesely DL 2005 Atrial natriuretic peptides: anticancer agents. Journal of Investigative Medicine 53 360-365.
73. Yano A, Fujii Y, Iwai A, Kageyama Y & Kihara K 2006 Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clinical Cancer Research 12 3003-3009.
74. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J et al. 1997 Six hundred fifty consecutive pancreaticoduodenectomies in the 1990's pathology, complications, and outcomes. Annals of Surgery 226 248-257.
75. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, Pitt HA & Lillemoe KD 1999 Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Annals of Surgery 229 613-622.